What are the side effects of Tofacitinib and are they serious?

Tofacitinib (Tofacitinib)is marketed for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA), psoriatic arthritis (PsA), and ankylosing spondylitis (AS) who have an inadequate response to or are intolerant to one or moreTNF blockers. Tofacitinib's oral solution is also indicated for the treatment of patients 2 years of age and older with active polyarticular juvenile idiopathic arthritis (pcJIA) who have an inadequate response to or intolerance to one or more TNF blockers.

The most common side effects of tofacitinib (which may affect up to 1 in 10 people) are headache, nose and throat infection and inflammation, diarrhea, nausea, and high blood pressure. The most common serious side effects are serious infections such as pneumonia (lung infection), shingles, urinary tract infection, cellulitis, diverticulitis, and appendicitis, as well as opportunistic infections that may occur in patients with weak immune systems. Adverse reactions such as drug allergy have occurred after tofacitinib was marketed (events such as angioedema and urticaria have been observed).

Tofacitinibhas been launched in China and has entered the scope of Class B medical insurance. The common specification is tofacitinib citrate tablets. The price paid by medical insurance is relatively cheap, but the reimbursement ratio is different in different regions, and the price after reimbursement will be different. Overseas, there are also tofacitinib generic drugs produced in other countries. The price of each box produced by a Bangladeshi pharmaceutical factory is around RMB 300 (the price may fluctuate due to the exchange rate). The ingredients of domestic original drugs and foreign generic drugs are basically the same, and the prices of different specifications will be different.